Newsletter Tool

Today’s Big News

May 28, 2024

AstraZeneca-Daiichi's Enhertu follow-up unable to prove overall survival benefit in phase 3

J&J scoops up another atopic dermatitis antibody in $1.25B Numab rights deal

Clinical-stage cancer biotech Actuate latest to eye summer IPO

Arrowhead's much-anticipated cholesterol drug hits the mark again in phase 2 hyperlipidemia trial

Insmed’s shares double as lung disease med powers past expectations in phase 3

Gilead pays $20M to join Cartography’s next-gen cancer medicine expedition

ILiAD's pertussis shot successfully joins Trojan Horse of childhood vaccines in phase 2

Innovent to take IL-23 psoriasis drug to Chinese regulators after phase 3 win

BioNTech pays $25M upfront to strengthen ADC bond with China's MediLink

Palleos Healthcare and OCT Global merge to form wide-reaching European CRO

Featured

AstraZeneca-Daiichi's Enhertu follow-up unable to prove overall survival benefit in phase 3

By James Waldron

Daiichi Sankyo and antibody-drug conjugate (ADC) partner AstraZeneca have already filed their Enhertu follow-up Dato-DXd with the FDA, but the latest clinical readout has cast a shadow over the application.

J&J scoops up another atopic dermatitis antibody in $1.25B Numab rights deal

By Annalee Armstrong

Not satisfied with just one new immunology deal this month, Johnson & Johnson is plunking down $1.25 billion in cash to scoop up rights to Numab Therapeutics’ phase 2-ready atopic dermatitis bispecific antibody.

Clinical-stage cancer biotech Actuate latest to eye summer IPO

By James Waldron

Could the IPO window really be reopening for the summer? The second biotech proposition in May suggests that the public markets are regaining its allure.

Arrowhead's much-anticipated cholesterol drug hits the mark again in phase 2 hyperlipidemia trial

By Annalee Armstrong

Arrowhead Pharmaceuticals’ hotly anticipated cholesterol disorder drug lowered key lipoproteins that increase the risk of cardiovascular disease in a phase 2 trial, supporting a late-stage program.

Insmed’s shares double as lung disease med powers past expectations in phase 3

By Annalee Armstrong

Insmed’s medicine didn’t just reduce exacerbations of a chronic lung disease in a phase 3 trial. The drug blew the primary endpoint out of the water with “very statistically significant” results, according to analysts.

Gilead pays $20M to join Cartography's next-gen cancer medicine expedition

By Gabrielle Masson

Gilead is drawing up $20 million cash to partner with Cartography Biosciences and navigate drug discovery for triple-negative breast cancer and adenocarcinoma, a common form of non-small cell lung cancer.

ILiAD's pertussis shot successfully joins Trojan horse of childhood vaccines in phase 2

By Annalee Armstrong

After proving the efficacy of a pertussis vaccine in preventing infection, ILiAD Biotechnologies’ next challenge was to add the shot to a Trojan horse lineup of childhood vaccines to see whether they can be co-administered.

Innovent to take IL-23 psoriasis drug to Chinese regulators after phase 3 win

By James Waldron

Innovent’s psoriasis contender to IL-23 drugs like Tremfya and Skyrizi cleared skin and improved the severity of disease in a phase 3 test, setting up the company to seek approval from Chinese regulators.

BioNTech pays $25M upfront to strengthen ADC bond with China's MediLink

By James Waldron

After penning a couple of antibody-drug conjugate deals in 2023, BioNTech has returned to MediLink Therapeutics to further pad out its portfolio.

Palleos Healthcare and OCT Global merge to form wide-reaching European CRO

By Helen Floersh

OCT Global SA and Palleos Healthcare have merged under the Palleos brand name, forming a new entity for CRO solutions across western and eastern Europe.

The top 20 drugs by worldwide sales in 2023

By Zoey Becker,Angus Liu,Kevin Dunleavy,Fraiser Kansteiner,Eric Sagonowsky

While the global pharmaceutical sales rankings naturally feature the biggest names in the business, each year some new products make their way onto the list. Last year, Merck's PD-1 oncology superstar Keytruda was 2023's bestseller, replacing Pfizer and BioNTech's COVID-19 vaccine Comirnaty.

Fierce podcasts

Don’t miss an episode

Automation, decentralization and the future of CAR-Ts: Advancements in cell & gene therapy manufacturing (Part III)

This week’s episode of “The Top Line,” is the final part of a three-part series diving into the latest advancements in cell and gene therapy manufacturing.

Hospitals grapple with generic drug supply shortages

From cell collection to commercial contracting: Advancements in cell & gene therapy manufacturing (Part II)

Resources

Whitepaper

Fresenius Medical Care gets 25x faster kidney disease insights

This detailed case study shows how Fresenius Medical Care achieved 25 times faster insights to help kidney disease patients, launching the world’s largest global database of dialysis care with fully anonymized patient data.

Sponsored by: Privacy Analytics, an IQVIA company

Whitepaper

Comprehensive Cell Solutions: Focus on Cellular Therapy Collections

Precision collection of cell therapy source material doesn’t happen by chance. Our new whitepaper illuminates the science and strategies for successful apheresis.

Sponsored by: Comprehensive Cell Solutions

Whitepaper

In Vitro Antibodies – Next-Gen Science Delivers Optimized Candidates

Learn how Specifica’s in vitro antibody discovery platform can deliver better antibodies than traditional immunization approaches.

Sponsored by: Specifica, a Q2 Solutions company

Whitepaper

Branded Digital Companions in Biopharma

This paper defines “digital companions” in biopharma, explores their value from the patient & company perspectives, & outlines a process for successfully fielding a new digital companion.

Presented by: Blue Matter, strategic consultants in the life sciences

eBook

Designing Patient-Centered Endpoint in Rare Disease Trials

To make every rare disease trial count, we design patient-centric, relevant strategies for sponsors and caregivers to produce impactful results every time.